reports
Creative Realities Reports Fiscal 2025 Second Quarter Results
Creative Realities Reports Fiscal 2025 Second Quarter Results Revenue Growth Picks Up as Year Progresses; Company on Track for Record 2025 LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced its financial results for the fiscal second quarter ended June 30, 2025. Highlights: Second quarter revenue of $13.0 million versus $13.1 million in the prior-year periodGross profit of $5.0 million for th...
- Wedbush Research
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
SE SEA ADS
STOK STOKE THERAPEUTICS
PASG PASSAGE BIO
ORIC ORIC PHARMACEUTICALS
GBIO GENERATION BIO
VOR VOR BIOPHARMA
PHVS PHARVARIS NV
ATXS ASTRIA THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
RNAC CARTESIAN THERAPEUTICS INC
MAZE MAZE THERAPEUTICS INC
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results an...
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors across $125 million private placement financing and $119 million ATM issuances; Following recent financing activity, ORIC concludes anticipated ATM facility usage In anticipation of potential initiation of regist...
Spero Therapeutics Announces Second Quarter 2025 Operating Results and...
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 Existing cash and earned and non-contingent development milestone payments from GSK provide anticipated runway to fund the Company’s cu...
- David Nierengarten
- Dennis Pak
- Martin Fan
TELA Bio Reports Second Quarter 2025 Financial Results
TELA Bio Reports Second Quarter 2025 Financial Results MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix produ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted ...
Janus Henderson Group Plc: 1 director
A director at Janus Henderson Group Plc sold 69,000 shares at 43.075USD and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Spero Therapeutics to Report Second Quarter 2025 Financial Results and...
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update. To access the ca...
Creative Realities Deploys Digital Display Solution at Circle K Mexico...
Creative Realities Deploys Digital Display Solution at Circle K Mexico to Drive Sales and Advance Sustainability Efforts Pilot leverages localized digital signage to reduce environmental impact and enhance customer engagement, setting the stage for potential nationwide rollout MEXICO CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today the successful deployment of a proof-of-concept (PoC) digital signage system at Circle K Mexico. The initiative, launched at a select location, includes...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025. These inducement grants were granted...
Creative Realities, Inc. Announces Second Quarter 2025 Earnings Releas...
Creative Realities, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call Information LOUISVILLE, K.Y., July 30, 2025 (GLOBE NEWSWIRE) -- ("Creative Realities," "CRI," or the "Company") (NASDAQ: ), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended June 30, 2025 before the market open on Wednesday, August 13, 2025. A conference call to review the results is scheduled for Wednesday, August 13, 2025, at 9:00 am Eastern Time, which will include prepared remarks and materials ...
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Co...
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at . About TELA Bio...
TELA Bio to Announce Second Quarter 2025 Financial Results
TELA Bio to Announce Second Quarter 2025 Financial Results MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInves...
Lesaka Webcast and Conference Call to Review Fourth Quarter and Year-E...
Lesaka Webcast and Conference Call to Review Fourth Quarter and Year-End 2025 Results JOHANNESBURG, July 09, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ:, JSE: LSK) ("Lesaka") today announced it will release fourth quarter and year-end 2025 results after the U.S. market close on September 3, 2025. Lesaka management will host a presentation webcast and conference call on September 4, 2025, at 8:00am EDT (2:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: Participants using the ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025. These inducement grants were grant...
Lesaka and Bank Zero Merge Ambitions in Landmark Transaction
Lesaka and Bank Zero Merge Ambitions in Landmark Transaction JOHANNESBURG, June 26, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) (“Lesaka” or “the group”) today announced that its wholly-owned subsidiary, Lesaka Technologies Proprietary Limited, has entered into an agreement to acquire (directly and indirectly) 100% of the issued ordinary shares of Bank Zero Mutual Bank (“Bank Zero”). The acquisition consideration will be settled through a combination of newly issued shares - such that the shareholders of Bank Zero will own approximately 12% of Lesaka’s full...
- Wedbush Research
- David Nierengarten
- Dennis Pak
- Martin Fan
Psychemedics Releases 2025 Workforce Insights Report
Psychemedics Releases 2025 Workforce Insights Report Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace Safety DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.